Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26333281 | 0.82 | MEN1 (0.42) | BAZ2BBRD4ARNR4A2TP53 | |
| SCHEMBL21180762 | 0.79 | MAPT (0.50) | ARTP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL22429678 | 0.79 | BAZ2B (0.39) | BAZ2BBRD4NR4A2TP53PKM | |
| SCHEMBL14002829 | 0.78 | BAZ2B (0.37) | BAZ2BBRD4ARNR4A2TP53 | |
| SCHEMBL6900641 | 0.78 | TOP1 (0.40) | BAZ2BBRD4ARNR4A2TP53 | |
| SCHEMBL18665455 | 0.77 | THRB (0.40) | BAZ2BBRD4NR4A2TP53PKM | |
| SCHEMBL13287985 | 0.77 | AR (0.35) | BAZ2BBRD4BACE1ARSMN1; SMN2 | |
| SCHEMBL3674837 | 0.77 | TDP1 (0.46) | BRD4ARHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL26831831 | 0.77 | LMNA (0.43) | BRD4TP53PKMMMP13ALDH1A1 | |
| SCHEMBL11199134 | 0.76 | CYP1A2 (0.47) | TP53PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024057020-A1 | ANTI-VIRAL COMPOUNDS | Infex Therapeutics Limited (GB) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023223055-A1 | ANTI-VIRAL COMPOUNDS | Infex Therapeutics Limited (GB) | 2023-11-23 | — | — | WO | disclosed |
| WO-2021159993-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR ASSOCIATED KINASE (IRAK) /FMS-LIKE RECEPTOR TYROSINE KINASE (FLT3), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PHARMABLOCK SCIENCES (NANJING) , INC. (CN) | 2021-08-19 | — | — | WO | disclosed |
| US-10358439-B2 | DNA binding agents with a minor groove binding tail | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10358439-B2 | DNA binding agents with a minor groove binding tail | TOP2B, TOP2A, TOP1 | BAZ2B 1330/4885BRD4 846/4885MKNK2 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.